• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

    4/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025.

    Key Financial Results

    First Quarter 2025 vs. First Quarter 2024

    • Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency.
    • Net earnings of $9.4 million versus $16.5 million.
    • Diluted EPS of $0.49 as compared with $0.86.
    • Adjusted diluted EPS(1) of $0.73 as compared with $0.86.
    • Adjusted EBITDA(2) of $30 million versus $33 million.
    • Direct selling Active Customers of 459,000 versus 494,000.
    • Hiya Active Monthly Subscribers of 224,000.
    • Company reiterates fiscal year 2025 outlook.

    Q1 2025 Financial Performance

    Consolidated Results

     

    Year-over-Year

    Sequentially

    Net Sales

    $250 million

    +10% (-$6 million or -2% FX impact)

    +17%

    Net Earnings

    $9.4 million

    -43%

    +111%

    Diluted EPS

    $0.49

    -43%

    +113%

    Adjusted Diluted EPS(1)

    $0.73

    -15%

    +15%

    Adjusted EBITDA(2)

    $30 million

    -10%

    +17%

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya

    "USANA is off to a solid start to the year as we continue to execute our growth strategy through our core direct sales business and our recently acquired direct-to-consumer business, Hiya. We are seeing encouraging signs in our direct sales business with net sales and Active Customers growing modestly on a sequential basis for the second consecutive quarter," said Jim Brown, President and Chief Executive Officer.

    "Hiya delivered strong growth in net sales and Active Monthly Subscribers. Hiya's momentum remains strong and should continue building as their team executes their plans to launch several new products this year, unveil another strategic partnership, and expand to additional channels. We continue to be confident in the growth trajectory of this business that is reaching a new customer demographic for us. On a consolidated basis, constant currency net sales grew 12% year-over-year and we are reiterating our full-year outlook.

    "While the global macroeconomic environment has become less certain since the beginning of the year due to volatility in international trade, tariffs, and consumer sentiment, the underlying demand for our products has remained strong. Operationally, our manufacturing facilities in the United States and mainland China uniquely position us to deliver the best possible shopping experience and value to our customers in every market around the world. Our supply chain team has actively managed our inventory levels and sourcing, and will continue to work with our stakeholders in each of our markets to navigate the increasingly dynamic operating environment."

    Q1 2025 Direct Selling Regional Results:

    Asia Pacific Region

     

    Year-

    Over-Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Net Sales

    $174 million

    -6%

    -4%

    +4%

    Active Customers

    374,000

    -5%

    n.a.

    +4%

    Asia Pacific Sub-Regions

     

    Year-Over-

    Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Greater China

    Net Sales

    $119 million

    -7%

    -5%

    +5%

    Active

    254,000

    -7%

    n.a.

    +3%

    Customers

    North Asia

    Net Sales

    $19 million

    -12%

    -4%

    +15%

    Active

    45,000

    Flat

    n.a.

    +18%

    Customers

    Southeast Asia Pacific

    Net Sales

    $36 million

    -1%

    No material FX impact

    -6%

    Active

    75,000

    -1%

    n.a.

    -3%

    Customers

    Americas and Europe Region

     

     

     

    Year-Over-

    Year

    Year-over-Year

    (Constant Currency)

    Sequentially

    Net Sales*

    $39 million

    -9%

    -4%

    -11%

    Active Customers

    85,000

    -14%

    n.a.

    -9%

    *Includes $2 million of ‘Other' as reported in the tables to this release

    Q1 2025 Hiya Direct to Consumer Results:

    Hiya

    Net Sales

    $37 million

    Active Monthly Subscribers

    224,000

    Balance Sheet and Share Repurchase Activity

    During the first quarter, the Company generated $15 million in operating cash flow and ended the quarter with $180 million in cash and cash equivalents and $23 million of debt. The Company repurchased 399,000 shares during the first quarter for an investment of $12 million with approximately $49 million remaining under the current share repurchase authorization as of the end of the first quarter.

    Fiscal Year 2025 Outlook

    The Company is reiterating its outlook for fiscal year 2025, as follows:

    Fiscal Year 2025 Outlook

     

    Range

    Consolidated net sales

    $920 million to $1.0 billion

    Net earnings

    $29 million to $41 million

    Diluted EPS

    $1.50 to $2.20

    Adjusted Diluted EPS(1)

    $2.35 to $3.00

    Adjusted EBITDA(2)

    $107 million to $123 million

    Net earnings, EPS and EBITDA figures represent amounts attributable to USANA and excludes the noncontrolling interest of 21.15% in Hiya

    "First quarter operating results were in line with internal expectations and reflected solid contributions from our direct selling business and strong top line growth from Hiya," said Doug Hekking, Chief Financial Officer. "We are reiterating our 2025 outlook and continue to anticipate consolidated top line growth of 8% to 17%. The impact of potential trade policies and tariffs remains highly uncertain at this time. As such, we have not reflected any potential impact in our financial guidance. Our primary focus, for now, is on the potential tariff impact associated with importing certain raw materials from China into the U.S. and importing certain raw materials from the U.S. into China. Our supply chain team continues to actively manage our exposure through efforts to selectively build inventory on exposed positions and seeking alternative sourcing relationships. Our team will continue to evaluate and pursue these strategies in an effort to mitigate the impact from tariffs or trade policies which become certain, and we will provide additional information as we gain greater visibility."

    The Company's outlook reflects:

    • Net sales from the direct selling business of $775 to $840 million, which includes an expected unfavorable currency exchange rate impact of approximately $30 million, or -4% on net sales;
    • Net sales from Hiya of $145 to $160 million, reflecting a year-over-year range of +29% to +42%;
    • Effective tax rate of 41.5% to 45.0%; and
    • Fiscal 2025 is a 53-week year and includes one additional week of sales compared to fiscal 2024. Prior to 2025, the last 53-week year was in fiscal 2020.

    _________________________

    (1) Adjusted Diluted Earnings Per Share is a non-GAAP financial measure. The Company excludes acquisition-related costs, such as business transaction costs, integration expense and amortization expense from acquisition related intangible assets in calculating Adjusted Diluted Earnings Per Share. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    (2) Adjusted EBITDA is a non-GAAP financial measure. Please refer to "Non-GAAP Financial Measures" and "Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (Non-GAAP)" in this press release for an explanation and reconciliation of this non-GAAP financial measure.

    Non-GAAP Financial Measures

    This press release contains the non-GAAP financial measures Adjusted EBITDA and Adjusted diluted EPS. Adjusted EBITDA is a Non-GAAP financial measure of earnings before interest, taxes, depreciation, and amortization that also excludes certain adjustments as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a Non-GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS.

    Adjusted EBITDA (non-GAAP) is net earnings (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (benefit from) provision for income taxes, depreciation and amortization, non-cash share-based compensation, and transaction-related expenses and integration costs for the Hiya acquisition. Adjusted EBITDA attributable to USANA (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to non-controlling interest related to Hiya.

    Adjusted diluted earnings per share (non-GAAP) is diluted earnings (loss) per share (its most directly comparable GAAP financial measure) adjusted for amortization of intangible assets, transaction-related expenses, and integration costs related to the Hiya acquisition.

    Management believes that Adjusted EBITDA (non-GAAP), Adjusted EBITDA attributable to USANA (non-GAAP), and Adjusted diluted earnings per share (non-GAAP), along with GAAP measures used by management, most appropriately reflect how the Company measures the business internally.

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP") and investors should not directly compare with or infer relationship from any of the Company's operating results presented in accordance with GAAP to Adjusted EBITDA and Adjusted diluted earnings per share. Non-GAAP financial measures have limitations in their usefulness to investors because they have no standardized meaning prescribed by GAAP and are not prepared under any comprehensive set of accounting rules or principles. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of non-GAAP financial information as a tool for comparison. As a result, the non-GAAP financial information is presented for supplemental informational purposes only and should not be considered in isolation from, or as a substitute for financial information presented in accordance with GAAP.

    Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)

     

     

     

    Quarter Ended

     

     

    29-Mar-25

     

    30-Mar-24

     

     

     

     

     

    Net earnings attributable to USANA (GAAP)

     

    $

    9,402

     

     

    $

    16,537

     

    Net earnings attributable to noncontrolling interest

     

     

    (112

    )

     

     

    -

     

    Net earnings

     

    $

    9,290

     

     

    $

    16,537

     

     

     

     

     

     

    Adjustments:

     

     

     

     

    Income taxes

     

     

    7,449

     

     

     

    10,574

     

    Interest (income) expense

     

     

    (312

    )

     

     

    (2,624

    )

    Depreciation and amortization

     

     

    5,790

     

     

     

    5,084

     

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    -

     

    Earnings before interest, taxes, depreciation, and amortization (EBITDA)

     

     

    26,672

     

     

     

    29,571

     

     

     

     

     

     

    Add EBITDA adjustments:

     

     

     

     

    Non-cash share-based compensation

     

     

    2,880

     

     

     

    3,669

     

    Transaction costs - Hiya

     

     

    577

     

     

     

    -

     

    Inventory step-up - Hiya

     

     

    582

     

     

     

    -

     

    Consolidated adjusted EBITDA

     

     

    30,711

     

     

     

    33,240

     

    Less: Adjusted EBITDA attributable to noncontrolling interest

     

     

    (954

    )

     

     

    -

     

    Adjusted EBITDA attributable to USANA

     

    $

    29,757

     

     

    $

    33,240

     

    Reconciliation of Diluted Earnings Per Share (GAAP) to Adjusted Diluted Earnings Per Share (non-GAAP)

     

     

     

    Quarter Ended

     

     

    29-Mar-25

     

    30-Mar-24

     

     

     

     

     

    Net earnings attributable to USANA (GAAP)

     

    $

    9,402

     

     

    $

    16,537

     

     

     

     

     

    Earnings per common share - Diluted (GAAP)

     

    $

    0.49

     

     

    $

    0.86

    Weighted Average common shares outstanding - Diluted

     

     

    19,085

     

     

     

    19,302

     

     

     

     

     

    Adjustment to net earnings:

     

     

     

     

    Transaction costs - Hiya

     

    $

    577

     

     

    $

    -

    Inventory step-up - Hiya

     

     

    582

     

     

     

    -

    Amortization of intangible assets - Hiya

     

     

    4,455

     

     

     

    -

    Adjustments to net earnings attributable to noncontrolling interest

     

     

    (1,066

    )

     

     

    -

    Income tax effect of adjustments to net earnings

     

     

    (4

    )

     

     

    -

     

     

     

     

     

    Adjusted net earnings attributable to USANA

     

    $

    13,946

     

     

    $

    16,537

     

     

     

     

     

    Adjusted earnings per common share - Diluted

     

    $

    0.73

     

     

    $

    0.86

    Weighted average common shares outstanding - Diluted

     

     

    19,085

     

     

     

    19,302

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, April 23, 2025 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as "expect," "enhance," "drive," "anticipate," "intend," "improve," "promote," "should," "believe," "continue," "plan," "goal," "opportunity," "estimate," "predict," "may," "will," "could," and "would," and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding Hiya's strong growth in 2025 and continued growth in the future; statements about the Company's long-term growth; and the statements under the sub-heading "Fiscal Year 2025 Outlook." Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control, including: risks relating to global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk that our Associate compensation plan, or changes that we make to the compensation plan, will not produce desired results, benefit our business or, in some cases, could harm our business; risk associated with our launch of new products or reformulated existing products; risks related to governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets, including potential adverse impact from tariffs, trade policies or other international disputes by and among the United States, China, or other markets that are important to the Company; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with early stage operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general; risk that the Hiya acquisition disrupts each company's current plans and operations; the diversion of the attention of the management teams of USANA and Hiya from ongoing business operations; the ability of to retain key personnel of Hiya; the ability to realize the benefits of the acquisition, including efficiencies and cost synergies; the ability to successfully integrate Hiya's business with USANA's business, at all or in a timely manner; and the amount of the costs, fees, expenses and charges related to the acquisition. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com. USANA also owns a 78.8% controlling ownership stake in Hiya Health Products, a children's health and wellness company with a variety of clean-label products. More information on Hiya can be found at www.hiyahealth.com.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Quarter Ended

     

    March 29,

    2025

    March 30,

    2024

    Net sales

    $

    249,539

     

    $

    227,800

     

    Cost of sales

     

    52,445

     

     

    43,069

     

    Gross profit

     

    197,094

     

     

    184,731

     

    Operating expenses:

     

     

    Associate incentives

     

    89,985

     

     

    95,758

     

    Selling, general and administrative

     

    91,438

     

     

    64,300

     

    Total operating expenses

     

    181,423

     

     

    160,058

     

    Earnings from operations

     

    15,671

     

     

    24,673

     

    Other income (expense):

     

     

    Interest income

     

    723

     

     

    2,676

     

    Interest expense

     

    (411

    )

     

    (52

    )

    Other, net

     

    756

     

     

    (186

    )

    Other income (expense), net

     

    1,068

     

     

    2,438

     

    Earnings before income taxes

     

    16,739

     

     

    27,111

     

    Income taxes

     

    7,449

     

     

    10,574

     

    Net earnings

     

    9,290

     

     

    16,537

     

    Less: Net earnings (loss) attributable to redeemable noncontrolling interest

     

    (112

    )

     

    —

     

    Net earnings attributable to USANA

    $

    9,402

     

    $

    16,537

     

     

     

     

    Earnings per common share attributable to USANA

     

     

    Basic

    $

    0.49

     

    $

    0.86

     

    Diluted

    $

    0.49

     

    $

    0.86

     

     

     

     

    Weighted average common shares outstanding

     

     

    Basic

     

    19,049

     

     

    19,174

     

    Diluted

     

    19,085

     

     

    19,302

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    March 29,

    2025

     

    As of

    December 28,

    2024

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    179,613

     

    $

    181,768

    Inventories

     

    73,557

     

     

    69,735

    Prepaid expenses and other current assets

     

    28,224

     

     

    27,684

    Total current assets

     

    281,394

     

     

    279,187

    Property and equipment, net

     

    94,245

     

     

    94,565

    Goodwill

     

    144,218

     

     

    144,168

    Intangible assets, net

     

    147,157

     

     

    151,823

    Deferred tax assets

     

    18,843

     

     

    19,644

    Other assets*

     

    60,739

     

     

    58,806

    Total assets

    $

    746,596

     

    $

    748,193

     

     

     

     

    LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST, AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    13,974

     

    $

    11,984

    Line of credit

     

    23,000

     

     

    23,000

    Other current liabilities

     

    100,409

     

     

    104,641

    Total current liabilities

     

    137,383

     

     

    139,625

    Deferred tax liabilities

     

    4,801

     

     

    4,073

    Other long-term liabilities

     

    20,539

     

     

    18,163

     

     

     

     

    Redeemable noncontrolling interest

     

    54,111

     

     

    54,223

     

     

     

     

    Stockholders' equity attributable to USANA

     

    529,762

     

     

    532,109

    Total liabilities, redeemable noncontrolling interest, and stockholders' equity

    $

    746,596

     

    $

    748,193

    *Includes noncurrent inventories of $2,864 and $2,688 as of 29-Mar-25 and 28-Dec-24, respectively. Total inventories were $76,421 and $72,423 as of 29-Mar-25 and 28-Dec-24, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

    Change from

    prior

    year

     

    Percent

    change

     

    Currency

    impact on

    sales

     

    % change

    excluding

    currency

    impact

     

    March 29, 2025

     

    March 30, 2024

     

     

     

     

    Direct Selling:

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    118,746

     

    47.6

    %

     

    $

    127,615

     

    56.0

    %

     

    $

    (8,869

    )

     

    (6.9

    %)

     

    $

    (2,015

    )

     

    (5.4

    %)

    Southeast Asia Pacific

     

    35,720

     

    14.3

    %

     

    $

    36,065

     

    15.9

    %

     

     

    (345

    )

     

    (1.0

    %)

     

     

    (118

    )

     

    (0.6

    %)

    North Asia

     

    18,941

     

    7.6

    %

     

    $

    21,421

     

    9.4

    %

     

     

    (2,480

    )

     

    (11.6

    %)

     

     

    (1,709

    )

     

    (3.6

    %)

    Asia Pacific Total

     

    173,407

     

    69.5

    %

     

     

    185,101

     

    81.3

    %

     

     

    (11,694

    )

     

    (6.3

    %)

     

     

    (3,842

    )

     

    (4.2

    %)

    Americas and Europe

     

    37,044

     

    14.8

    %

     

     

    41,047

     

    18.0

    %

     

     

    (4,003

    )

     

    (9.8

    %)

     

     

    (1,749

    )

     

    (5.5

    %)

    Direct Selling total

     

    210,451

     

    84.3

    %

     

     

    226,148

     

    99.3

    %

     

     

    (15,697

    )

     

    (6.9

    %)

     

     

    (5,591

    )

     

    (4.5

    %)

    Hiya

     

    37,089

     

    14.9

    %

     

     

    —

     

    —

    %

     

     

    37,089

     

     

    N/A

     

     

     

    —

     

     

    N/A

     

    Other

     

    1,999

     

    0.8

    %

     

     

    1,652

     

    0.7

    %

     

     

    347

     

     

    21.0

    %

     

     

    —

     

     

    21.0

    %

    Consolidated total

    $

    249,539

     

    100.0

    %

     

    $

    227,800

     

    100.0

    %

     

    $

    21,739

     

     

    9.5

    %

     

    $

    (5,591

    )

     

    12.0

    %

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    DIRECT SELLING ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     

    Direct Selling Active Associates by Region(1)

     

    (unaudited)

     

     

    As of

    March 29, 2025

     

    As of

    March 30, 2024

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    65,000

     

    35.3

    %

     

    71,000

     

    36.1

    %

    Southeast Asia Pacific

    48,000

     

    26.1

    %

     

    51,000

     

    25.9

    %

    North Asia

    33,000

     

    17.9

    %

     

    30,000

     

    15.2

    %

    Asia Pacific Total

    146,000

     

    79.3

    %

     

    152,000

     

    77.2

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    38,000

     

    20.7

    %

     

    45,000

     

    22.8

    %

     

    184,000

     

    100.0

    %

     

    197,000

     

    100.0

    %

     

    Direct Selling Active Preferred Customers by Region(2)

     

    (unaudited)

     

     

    As of

    March 29, 2025

     

    As of

    March 30, 2024

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    189,000

     

    68.7

    %

     

    203,000

     

    68.3

    %

    Southeast Asia Pacific

    27,000

     

    9.8

    %

     

    25,000

     

    8.4

    %

    North Asia

    12,000

     

    4.4

    %

     

    15,000

     

    5.1

    %

    Asia Pacific Total

    228,000

     

    82.9

    %

     

    243,000

     

    81.8

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    47,000

     

    17.1

    %

     

    54,000

     

    18.2

    %

     

    275,000

     

    100.0

    %

     

    297,000

     

    100.0

    %

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    OPERATING RESULTS AS A PERCENTAGE OF NET SALES

     

     

    Quarter Ended

     

    29-Mar-25

     

    30-Mar-24

     

    Direct Selling &

    Other

    Hiya

    Consolidated

     

    Direct Selling &

    Other

    Hiya

    Consolidated

    Net Sales

    100.0%

    100.0%

    100.0%

     

    100.0%

    N/A

    100.0%

    Cost of Sales

    18.1%

    38.0%

    21.0%

     

    18.9%

    N/A

    18.9%

    Gross Profit

    81.9%

    62.0%

    79.0%

     

    81.1%

    N/A

    81.1%

    Operating Expenses

     

     

     

     

     

     

     

    Associate Incentives

    42.4%

    0.0%

    36.1%

     

    42.0%

    N/A

    42.0%

    SG&A

    32.0%

    63.4%

    36.6%

     

    28.3%

    N/A

    28.3%

    Total operating expenses

    74.3%

    63.4%

    72.7%

     

    70.3%

    N/A

    70.3%

    Earnings from operations

    7.6%

    -1.4%

    6.3%

     

    10.8%

    N/A

    10.8%

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

    0.1%

    12.0%

    1.9%

     

    0.1%

    N/A

    0.1%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250422312631/en/

    Investor contact: Andrew Masuda

    Investor Relations

    (801) 954-7201

    [email protected]

    Media contact: Sarah Searle

    (801) 954-7626

    [email protected]

    Get the next $USNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Kevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1

      SALT LAKE CITY, May 1, 2025 /PRNewswire/ -- Kevin Guest, Executive Chairman at USANA Health Sciences (NYSE:USNA) and acclaimed author of All the Right Reasons, 12 Timeless Principles for Living a Life in Harmony, is sharing valuable insights for professionals striving to reach their peak potential. As part of Executive Coaching Day on May 1, Guest is combining decades of leadership experience with principles outlined in his bestselling book to offer actionable steps for success both in the boardroom and in life. "True success isn't just about achieving your goals; it's about l

      5/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award Winner

      SALT LAKE CITY, April 28, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, announced today that its Celavive Postbiotic Rescue Serum was named as a winner in Good Housekeeping's 2025 Beauty Awards. The full list of awards can be found here. To learn more about USANA and the science behind its products, please visit USANA.com. "We're so excited that our Postbiotic Rescue Serum has been named a Good Housekeeping 2025 Beauty Award winner," said Brent Neidig, USANA's chief commercial officer. "Our product and R&D teams have put so much time

      4/28/25 7:27:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Financials

    Live finance-specific insights

    See more
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Schedules First Quarter 2025 Earnings Release and Conference Call

      USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter 2025 results will be released after the close of market on Tuesday, April 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, April 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures hi

      4/8/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) (the "Company") today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC ("Hiya") on December 23, 2024. Consequently, the Company's fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya's operating results, which were not significant to the Company's consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adju

      2/25/25 4:10:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    SEC Filings

    See more
    • SEC Form S-8 filed by USANA Health Sciences Inc.

      S-8 - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/21/25 4:07:17 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by USANA Health Sciences Inc.

      DEFA14A - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/1/25 4:44:16 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • DA Davidson initiated coverage on USANA with a new price target

      DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

      4/14/22 7:45:27 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Ding Xia

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:40:18 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Wood Timothy E

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:39:07 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Director Pelosi Peggie

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/21/25 2:37:05 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/24 10:49:58 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/13/23 11:26:45 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

      SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

      2/11/22 3:48:24 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

      SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

      7/1/24 7:13:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care